stockrow
Friday 6 November 2026
Export DMTKQ’s income statement to Excel — free account
DermTech, Inc.
DMTKQ Healthcare Diagnostics & Research
DermTech, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.3 million, up 5.36% from fiscal 2022.
0.00
0.00
NaN
Follow DMTKQ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM Mar ’24 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 3 | 6 | 12 | 15 | 15 | 16 | +44.3% | 16 | 17 | 25 | +18.4% | |
| Gross margin, % | — | — | 0.00 | 0.00 | (7.58) | 1.78 | (1.63) | 10.76 | 4.46 | 1.80 | 8.51 | +1.8 pt | ||||||
| EBT | — | — | 0 | 1 | (10) | (20) | (36) | (78) | (117) | (101) | (90) | +620.6% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | (409.66) | (598.39) | (619.83) | (661.72) | (803.71) | (659.57) | (572.19) | (659.6) pt | ||||||
| Net income | — | — | 0 | 0 | (10) | (20) | (36) | (78) | (117) | (101) | (90) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.55 | 0.48 | 0.35 | 0.41 | 0.48 | 0.47 | 0.45 | n/m | |||||
| Earnings | — | — | — | 0.03 | (2.27) | (2.81) | (2.08) | (2.71) | (3.88) | (3.09) | (2.70) | n/m | ||||||
| Cash flow | — | — | 0.00 | 0.00 | (1.72) | (2.54) | (1.69) | (2.15) | (3.17) | (2.36) | (2.08) | n/m | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | (0.03) | (0.11) | (0.09) | (0.11) | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | 0.00 | 0.00 | (1.73) | (2.57) | (1.80) | (2.24) | (3.28) | (2.39) | (2.08) | n/m | ||||||
| Book value | — | — | 0.00 | 0.01 | (1.21) | 1.78 | 3.64 | 7.95 | 4.41 | 1.75 | 1.15 | n/m | ||||||
| Shares, m | — | — | — | 2 | 4 | 7 | 17 | 29 | 30 | 33 | 33 | +61.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 25.82 | 93.60 | 38.55 | 3.77 | 3.54 | 0.00 | 27.5 | ||||||
| P/B | — | — | — | — | 0.00 | 6.96 | 8.91 | 1.99 | 0.41 | 0.95 | 0.00 | 3.2 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 21.40 | 83.08 | 19.54 | (4.92) | (0.11) | (2.49) | 19.8 | ||||||
| EV/FCF | — | — | — | — | (60.35) | (4.00) | (16.02) | (3.57) | 0.72 | 0.02 | 0.53 | (13.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | (1) | (8) | (18) | (29) | (62) | (95) | (77) | (72) | n/m | |||||
| Capex | — | — | 0 | 0 | 0 | 0 | (2) | (3) | (3) | (1) | (1) | n/m | ||||||
| Free cash flow | — | — | 0 | (1) | (8) | (18) | (31) | (65) | (99) | (78) | (72) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 0 | (5) | 11 | 61 | 221 | 120 | 48 | 32 | n/m | |||||
| Net debt | — | — | 0 | 0 | (4) | (15) | (62) | (225) | (126) | (56) | (39) | +200.9% | ||||||
| Shareholders’ equity | — | — | 0 | 0 | (5) | 12 | 62 | 230 | 132 | 57 | 40 | +207.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (0.10) | 1.17 | (13.12) | (131.35) | (82.91) | (49.25) | (51.81) | (62.28) | (64.00) | (62.2) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1,040.52) | (1,182.97) | (4,806.29) | (5,493.45) | (4,806.3) pt | ||||||
| ROE | — | — | (1.03) | 0.00 | 5,636.06 | (230.20) | (98.15) | (53.74) | (64.46) | (106.46) | (121.75) | (105.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 64 | 118 | 258 | 279 | 208 | — | +116.9% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 | 0.05 | 0.07 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Mar 2024 · fundamentals updated 26 Oct 2026
DermTech, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NDRA ENDRA Life Sciences Inc. | $7.5M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | Compare |
| XWEL XWELL, Inc. | $6.1M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $3.3M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | Compare |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | |
| ADVB Advanced Biomed Inc. | $3.1M | 0.3× | — | — | n/m | −101.33% (below 0%: shrinking) | — | 0.00% | Compare |
| AWHL Aspira Women's Health Inc. | $2.4M | — (loss-making) | — (loss-making) | −14.89% (below 0%: shrinking) | n/m | −24.57% (below 0%: shrinking) | 55.28% | (89.69%) | Compare |
| ISPC iSpecimen Inc. | $2.0M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | Compare |
| PRPH ProPhase Labs, Inc. | $1.2M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 22.35% | (261.62%) | Compare |
| Median of peers | $3.2M | — | — | −14.89% | — | −24.13% | 27.98% | (155.23%) |